Treatment of ovarian cancer with a tropism modified oncolytic adenovirus

Cancer Res. 2002 Mar 1;62(5):1266-70.

Abstract

Ad5-Delta 24RGD is an adenovirus that is selectively replication competent in cells defective in the Rb/p16 pathway, such as ovarian cancer cells. The fiber of Ad5-Delta 24RGD contains an integrin binding RGD-4C motif, allowing Coxsackie adenovirus receptor-independent infection of cancer cells. Oncolysis of cell lines was similar to that of a wild-type control, and replication in primary tumor material was shown using a novel three-dimensional spheroid model. Finally, an orthotopic murine model of peritoneally disseminated ovarian cancer was used to test i.p. administration to tumor-bearing animals. Injection of the agent resulted in eradication of i.p. disease, whereas control animals expired (P < 0.0001). These results suggest that Ad5-Delta 24RGD could be useful for treatment of ovarian cancer in humans.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adenoviridae / genetics*
  • Animals
  • Female
  • Genetic Therapy*
  • Mice
  • Mice, SCID
  • Oligopeptides / genetics*
  • Ovarian Neoplasms / therapy*
  • Spheroids, Cellular
  • Virus Replication

Substances

  • Oligopeptides
  • arginyl-glycyl-aspartic acid